CRIS Current Research Information System

DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.284
NA - Nord America 1.187
EU - Europa 1.001
SA - Sud America 146
AF - Africa 112
OC - Oceania 6
Totale 4.736
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.162
SG - Singapore 961
CN - Cina 672
DE - Germania 303
HK - Hong Kong 244
IT - Italia 171
VN - Vietnam 146
KR - Corea 129
BR - Brasile 112
SE - Svezia 103
NL - Olanda 102
GB - Regno Unito 64
FI - Finlandia 58
IN - India 56
CI - Costa d'Avorio 45
FR - Francia 44
IE - Irlanda 43
SC - Seychelles 39
RU - Federazione Russa 32
ID - Indonesia 23
JP - Giappone 21
TG - Togo 18
BG - Bulgaria 17
AT - Austria 15
AR - Argentina 13
CA - Canada 12
BE - Belgio 10
PL - Polonia 10
BD - Bangladesh 9
MX - Messico 9
CH - Svizzera 8
CO - Colombia 7
JO - Giordania 7
AU - Australia 6
ES - Italia 6
EC - Ecuador 5
LT - Lituania 5
ZA - Sudafrica 5
CL - Cile 4
IQ - Iraq 4
AE - Emirati Arabi Uniti 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
PH - Filippine 2
PY - Paraguay 2
TR - Turchia 2
UA - Ucraina 2
VE - Venezuela 2
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
MG - Madagascar 1
MY - Malesia 1
NG - Nigeria 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 4.736
Salva come PNG Salva come JPEG
Città #
Singapore 717
Hefei 299
Ashburn 250
Hong Kong 243
Santa Clara 154
Seoul 128
Chandler 96
Beijing 71
Boardman 63
Los Angeles 52
Abidjan 45
Ho Chi Minh City 44
Dublin 42
Krefeld 41
Helsinki 40
Southend 37
Buffalo 35
Dallas 33
Munich 32
Hanoi 30
Princeton 28
Fairfield 27
Bengaluru 26
Falkenstein 26
Amsterdam 25
Bologna 23
Frankfurt am Main 22
Tokyo 21
Lomé 18
Redondo Beach 18
Jakarta 17
New York 17
Sofia 17
Nuremberg 16
Seattle 16
Shanghai 16
Bad Bellingen 15
Lappeenranta 15
Rome 14
Wilmington 12
Cambridge 11
Houston 11
Milan 11
Woodbridge 11
Brussels 10
Chicago 10
Des Moines 10
Düsseldorf 10
São Paulo 10
Berlin 9
Tongling 9
Brooklyn 8
London 8
Rio de Janeiro 8
San Diego 8
Shenzhen 8
Amman 7
Guangzhou 7
Mexico City 7
Turin 7
Ann Arbor 6
Da Nang 6
Fort Worth 6
Genoa 6
Monzuno 6
San Francisco 6
Trento 6
Bern 5
Castel Maggiore 5
Denver 5
Lauterbourg 5
Nanjing 5
Toronto 5
Warsaw 5
Bexley 4
Changsha 4
Council Bluffs 4
Dongguan 4
Foshan 4
Harbin 4
Naples 4
Orem 4
Ottawa 4
Perth 4
Phoenix 4
Ravenna 4
Shijiazhuang 4
Tampa 4
Wroclaw 4
Yubileyny 4
Arezzo 3
Bắc Ninh 3
Cao Lanh 3
Curitiba 3
Ha Long 3
Haiphong 3
Hebei 3
Padova 3
Piracicaba 3
Qingdao 3
Totale 3.192
Salva come PNG Salva come JPEG
Nome #
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 249
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 161
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 159
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 151
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients 138
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome 136
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 130
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 126
Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications 125
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 123
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 120
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. 120
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 115
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 113
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 113
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 111
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 109
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 103
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 102
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 95
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 92
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 89
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 82
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 81
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer 79
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 78
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 74
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 74
New prognostic biomarkers in metastatic castration-resistant prostate cancer 70
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 69
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 67
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 63
CAR-T cell therapy: A potential new strategy against prostate cancer 54
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 54
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 54
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 53
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 50
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 50
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 49
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 49
Immunotherapy for prostate cancer: Where we are headed 48
Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers 45
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 43
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 43
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 42
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 41
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 41
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 40
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 40
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 39
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 38
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 38
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma 38
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 38
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 37
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 36
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 35
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 34
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 33
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 33
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 32
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 30
Bevacizumab as maintenance treatment in patients with ovarian cancer: Wait for BRCA testing 27
Psychosocial issues in long-term survivors of testicular cancer 27
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) 14
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 12
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors 7
null 2
Totale 4.863
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202131 0 0 0 0 0 1 0 2 5 0 1 22
2021/2022234 4 0 3 6 9 4 25 16 5 50 74 38
2022/2023343 20 48 11 47 22 44 8 16 72 9 20 26
2023/2024364 10 17 5 3 9 39 15 15 204 21 17 9
2024/20251.699 100 207 121 152 230 108 52 68 17 138 101 405
2025/20262.088 357 423 386 363 452 107 0 0 0 0 0 0
Totale 4.863